AR079205A1 - Morfolinotiazoles como moduladores alostericos positivos alfa 7 - Google Patents
Morfolinotiazoles como moduladores alostericos positivos alfa 7Info
- Publication number
- AR079205A1 AR079205A1 ARP100104379A ARP100104379A AR079205A1 AR 079205 A1 AR079205 A1 AR 079205A1 AR P100104379 A ARP100104379 A AR P100104379A AR P100104379 A ARP100104379 A AR P100104379A AR 079205 A1 AR079205 A1 AR 079205A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- alkyloxy
- trifluoromethyl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- -1 2,2-difluoro-1,3-benzodioxolyl Chemical group 0.000 abstract 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 2
- 230000003281 allosteric effect Effects 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 abstract 1
- QHSGLIXDBAERBR-UHFFFAOYSA-N 4-(1,3-thiazol-2-yl)morpholine Chemical class C1COCCN1C1=NC=CS1 QHSGLIXDBAERBR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a derivados morfolinotiazol y sus sales farmacéuticamente aceptables, procesos para prepararlos, composiciones farmacéuticas que los contienen y sus usos en terapia. La solicitud en particular se refiere a moduladores alostéricos positivos de receptores acetilcolina nicotínicos, dichos moduladores alostéricos positivos que tengan la capacidad de aumentar la eficacia de agonistas del receptor nicotínico. Reivindicacion 1: Un compuesto que tiene la formula (1) o un isomero estereoquímico del mismo, donde R1 es alquilo C1-6, alquilo C1-6 sustituido con 1, 2 o 3 sustituyentes halogeno, alquilo C1-6 sustituido con 1 grupo ciano, alquilo C1-6 sustituido con 1 grupo heteroarilo, cicloalquilo C3-6, cicloalquilo C3-6 sustituido con 1, 2, 3 o 4 grupos metilo, cicloalquilo C3-6 sustituido con 1 grupo hidroxi, cicloalquilo C3-6-alquilo C1-6, alquiloxi C1-6-alquilo C1-6, halo alquiloxi C1-4-alquilo C1-6, tetrahidrofurilo, arilo, heteroarilo, pirrolidinilo, pirrolidinilo sustituido con 1 grupo alquilo C1-4, o tetrahidrofurilo sustituido con 1, 2 o 3 sustituyentes seleccionados de metilo y oxo; arilo es 2,2-difluoro-1,3-benzodioxolil; fenilo; o fenilo sustituido con 1, 2 o 3 sustituyentes seleccionados de halogeno, trifluorometilo, trifluorometoxi, ciano, alquilo C1-6, alquiloxi C1-4, y aminosulfonilo; heteroarilo es un radical heterocíclico aromático mono o bicíclico que contiene por lo menos un heteroátomo seleccionado de N, O y S, opcionalmente sustituido con 1, 2 o de ser posible con 3 sustituyentes seleccionados de alquilo C1-4, alquiloxi C1-4, cicloalquilo C3-6, y trifluorometilo; R2 y R3 son de manera independiente H, alquilo C1-4 o trifluorometilo; o R2 y R3 se toman juntos para formar 1,2-etanodiilo o 1,3-propanodiil; Ar es un resto de formula (2) o (3); R4 y R5 son de manera independiente H, alquilo C1-4, trifluorometilo, cicloalquilo C3-6 o alquiloxi C1-4; o una sal de adicion ácida del mismo, o un solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09177347 | 2009-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079205A1 true AR079205A1 (es) | 2012-01-04 |
Family
ID=42010343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104379A AR079205A1 (es) | 2009-11-27 | 2010-11-26 | Morfolinotiazoles como moduladores alostericos positivos alfa 7 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8637510B2 (es) |
| EP (1) | EP2504333B1 (es) |
| JP (1) | JP5636434B2 (es) |
| KR (1) | KR101749953B1 (es) |
| CN (1) | CN102639530B (es) |
| AR (1) | AR079205A1 (es) |
| AU (1) | AU2010323175B2 (es) |
| BR (1) | BR112012012657A2 (es) |
| CA (1) | CA2780218C (es) |
| CL (1) | CL2012001366A1 (es) |
| CO (1) | CO6531464A2 (es) |
| DK (1) | DK2504333T3 (es) |
| EA (1) | EA020275B1 (es) |
| ES (1) | ES2549917T3 (es) |
| IL (1) | IL219926A0 (es) |
| JO (1) | JO3078B1 (es) |
| MX (1) | MX349585B (es) |
| MY (1) | MY160728A (es) |
| NZ (1) | NZ600138A (es) |
| PL (1) | PL2504333T3 (es) |
| SG (1) | SG181054A1 (es) |
| TW (1) | TWI473803B (es) |
| UA (1) | UA106636C2 (es) |
| WO (1) | WO2011064288A1 (es) |
| ZA (1) | ZA201203856B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| ES2424023T3 (es) * | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-triazoles trisustituidos |
| JO2784B1 (en) * | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| CA2714662C (en) * | 2008-03-19 | 2016-05-10 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators |
| CL2009001125A1 (es) * | 2008-05-09 | 2011-02-11 | Janssen Pharmaceutica Nv | Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. |
| KR20180101641A (ko) | 2010-05-17 | 2018-09-12 | 포럼 파마슈티칼즈 인크. | (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태 |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| MX344701B (es) | 2011-02-03 | 2017-01-03 | Lupin Ltd | Derivados de pirrol como moduladores de nachr alfa 7. |
| AP3649A (en) | 2011-02-23 | 2016-03-18 | Lupin Ltd | Heteroaryl derivatives as alpha7 nachr modulators |
| CA2829860A1 (en) | 2011-03-31 | 2012-10-04 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
| IN2014MN01756A (es) | 2012-03-06 | 2015-07-03 | Lupin Ltd | |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| WO2014072957A1 (en) | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| WO2014111839A1 (en) | 2013-01-16 | 2014-07-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| JP2016512225A (ja) | 2013-03-13 | 2016-04-25 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体 |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| EP3010899A1 (en) | 2013-06-17 | 2016-04-27 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| HRP20221497T1 (hr) | 2016-08-19 | 2023-02-17 | The University Of Bristol | Derivati citizina za liječenje ovisnosti |
| EP3856180A1 (en) * | 2018-09-24 | 2021-08-04 | Astrazeneca AB | Azd0328 dosage regime for treating cognitive impairment |
| US20220347166A1 (en) * | 2019-10-21 | 2022-11-03 | Cambridge Cognition Limited | Schizophrenic Disorder Treatment using Combination Therapy |
| CN115317480B (zh) * | 2022-09-01 | 2023-05-16 | 新乡医学院 | N-(3-甲基-5-异噻唑基)-2-氧代-3-(2h)-苯并噁唑乙酰胺的药物应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479510B2 (en) * | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US8178570B2 (en) | 2003-04-09 | 2012-05-15 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| BRPI0609464A2 (pt) | 2005-05-23 | 2010-04-13 | Japan Tobacco Inc | composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo |
| EA015034B1 (ru) * | 2005-09-13 | 2011-04-29 | Янссен Фармацевтика Н.В. | 2-анилин-4-арилзамещенные тиазольные производные |
| CN101374810A (zh) * | 2006-01-18 | 2009-02-25 | 锡耶纳生物技术股份公司 | α7烟碱型乙酰胆碱受体的调节剂及其治疗用途 |
| JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| KR20100135911A (ko) | 2008-04-17 | 2010-12-27 | 글락소 그룹 리미티드 | 니코틴성 아세틸콜린 수용체 아형 알파-7의 조절인자로서의 인돌 |
| MX2016002975A (es) | 2013-09-09 | 2016-10-21 | Melinta Therapeutics Inc | Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos. |
-
2010
- 2010-11-10 JO JOP/2010/0392A patent/JO3078B1/ar active
- 2010-11-25 CA CA2780218A patent/CA2780218C/en not_active Expired - Fee Related
- 2010-11-25 JP JP2012540425A patent/JP5636434B2/ja not_active Expired - Fee Related
- 2010-11-25 UA UAA201205490A patent/UA106636C2/uk unknown
- 2010-11-25 EA EA201290394A patent/EA020275B1/ru unknown
- 2010-11-25 EP EP10782609.1A patent/EP2504333B1/en active Active
- 2010-11-25 ES ES10782609.1T patent/ES2549917T3/es active Active
- 2010-11-25 MX MX2012006082A patent/MX349585B/es active IP Right Grant
- 2010-11-25 WO PCT/EP2010/068193 patent/WO2011064288A1/en not_active Ceased
- 2010-11-25 SG SG2012038451A patent/SG181054A1/en unknown
- 2010-11-25 PL PL10782609T patent/PL2504333T3/pl unknown
- 2010-11-25 CN CN201080053890.2A patent/CN102639530B/zh not_active Expired - Fee Related
- 2010-11-25 KR KR1020127015644A patent/KR101749953B1/ko not_active Expired - Fee Related
- 2010-11-25 US US13/512,464 patent/US8637510B2/en not_active Expired - Fee Related
- 2010-11-25 NZ NZ600138A patent/NZ600138A/xx not_active IP Right Cessation
- 2010-11-25 BR BR112012012657A patent/BR112012012657A2/pt not_active Application Discontinuation
- 2010-11-25 DK DK10782609.1T patent/DK2504333T3/en active
- 2010-11-25 AU AU2010323175A patent/AU2010323175B2/en not_active Ceased
- 2010-11-25 MY MYPI2012002342A patent/MY160728A/en unknown
- 2010-11-26 TW TW99140892A patent/TWI473803B/zh not_active IP Right Cessation
- 2010-11-26 AR ARP100104379A patent/AR079205A1/es unknown
-
2012
- 2012-04-20 CO CO12065796A patent/CO6531464A2/es active IP Right Grant
- 2012-05-22 IL IL219926A patent/IL219926A0/en active IP Right Grant
- 2012-05-25 CL CL2012001366A patent/CL2012001366A1/es unknown
- 2012-05-25 ZA ZA2012/03856A patent/ZA201203856B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| MX2014011752A (es) | Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii. | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR091490A1 (es) | Antagonistas de iap | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| CL2020002550A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| MX2017011650A (es) | Inhibidores de kv1.3 y su aplicacion medica. | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |